Vesalius Longevity Labs Inc.

Vesalius Longevity Labs Inc.

1.50
CAD
-0.28
(-15.73%)
Vesalius Longevity Labs Inc.
CSE:VLAB
(Canadian Securities Exchange)

Recent

price

1.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available
Business
Vesalius Longevity Labs is a peptide and longevity company focused on developing and distributing advanced, physician-prescribed peptide therapeutics. The company is based in Scottsdale, AZ. The company offers a portfolio of peptide formulations delivered via subcutaneous injections, transdermal patches, intranasal sprays, oral capsules, and topical applications, exclusively through licensed healthcare providers by prescription. Vesalius operates a B2Doctor distribution model, serving independent providers and aligning its manufacturing process with cGMP standards, including third-party verification and chain-of-custody documentation. The company is led by clinical researchers, medical doctors, and biotech professionals, and bridges traditional medicine with emerging wellness approaches. Vesalius targets licensed healthcare professionals, with its website and products not intended for direct consumer sales or FDA-evaluated medical claims.